Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model - PubMed (original) (raw)
. 2013 Nov 15;19(22):6151-62.
doi: 10.1158/1078-0432.CCR-13-1189. Epub 2013 Sep 12.
Miguel F Sanmamed, Inmaculada Rodriguez, Asis Palazon, Ivan Martinez-Forero, Sara Labiano, Sandra Hervas-Stubbs, Bruno Sangro, Carmen Ochoa, Ana Rouzaut, Arantza Azpilikueta, Elixabet Bolaños, Maria Jure-Kunkel, Ines Gütgemann, Ignacio Melero
Affiliations
- PMID: 24030703
- DOI: 10.1158/1078-0432.CCR-13-1189
Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model
Aizea Morales-Kastresana et al. Clin Cancer Res. 2013.
Abstract
Purpose: Immunostimulatory monoclonal antibodies (ISmAb) that unleash antitumor immune responses are showing efficacy in cancer clinical trials. Anti-B7-H1 (PD-L1) monoclonal antibodies (mAb) block a critical inhibitory pathway in T cells, whereas anti-CD137 and OX40 mAbs provide T-cell costimulation. A combination of these ISmAbs (anti-CD137 + anti-OX40 + anti-B7-H1) was tested using a transgenic mouse model of multifocal and rapidly progressing hepatocellular carcinoma, in which c-myc drives transformation and cytosolic ovalbumin (OVA) is expressed in tumor cells as a model antigen.
Experimental design: Flow-cytometry and immunohistochemistry were used to quantify tumor-infiltrating lymphocytes (TIL) elicited by treatment and assess their activation status and cytolytic potential. Tolerance induction and its prevention/reversal by treatment with the combination of ISmAbs were revealed by in vivo killing assays.
Results: The triple combination of ISmAbs extended survival of mice bearing hepatocellular carcinomas in a CD8-dependent fashion and synergized with adoptive T-cell therapy using activated OVA-specific TCR-transgenic OT-1 and OT-2 lymphocytes. Mice undergoing therapy showed clear increases in tumor infiltration by activated and blastic CD8(+) and CD4(+) T lymphocytes containing perforin/granzyme B and expressing the ISmAb-targeted receptors on their surface. The triple combination of ISmAbs did not result in enhanced OVA-specific cytotoxic T lymphocyte (CTL) activity but other antigens expressed by cell lines derived from such hepatocellular carcinomas were recognized by endogenous TILs. Adoptively transferred OVA-specific OT-1 lymphocytes into tumor-bearing mice were rendered tolerant, unless given the triple mAb therapy.
Conclusion: Extension of survival and dense T-cell infiltrates emphasize the translational potential of combinational immunotherapy strategies for hepatocellular carcinoma. Clin Cancer Res; 19(22); 6151-62. ©2013 AACR.
Similar articles
- Targeting spatiotemporal expression of CD137 on tumor-infiltrating cytotoxic T lymphocytes as a novel strategy for agonistic antibody therapy.
Noji S, Hosoi A, Takeda K, Matsushita H, Morishita Y, Seto Y, Kakimi K. Noji S, et al. J Immunother. 2012 Jul;35(6):460-72. doi: 10.1097/CJI.0b013e31826092db. J Immunother. 2012. PMID: 22735804 - Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.
Weigelin B, Bolaños E, Teijeira A, Martinez-Forero I, Labiano S, Azpilikueta A, Morales-Kastresana A, Quetglas JI, Wagena E, Sánchez-Paulete AR, Chen L, Friedl P, Melero I. Weigelin B, et al. Proc Natl Acad Sci U S A. 2015 Jun 16;112(24):7551-6. doi: 10.1073/pnas.1506357112. Epub 2015 Jun 1. Proc Natl Acad Sci U S A. 2015. PMID: 26034288 Free PMC article. - The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy.
Palazón A, Martínez-Forero I, Teijeira A, Morales-Kastresana A, Alfaro C, Sanmamed MF, Perez-Gracia JL, Peñuelas I, Hervás-Stubbs S, Rouzaut A, de Landázuri MO, Jure-Kunkel M, Aragonés J, Melero I. Palazón A, et al. Cancer Discov. 2012 Jul;2(7):608-23. doi: 10.1158/2159-8290.CD-11-0314. Epub 2012 Jun 19. Cancer Discov. 2012. PMID: 22719018 - Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.
Durgeau A, Virk Y, Corgnac S, Mami-Chouaib F. Durgeau A, et al. Front Immunol. 2018 Jan 22;9:14. doi: 10.3389/fimmu.2018.00014. eCollection 2018. Front Immunol. 2018. PMID: 29403496 Free PMC article. Review. - Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy.
Sanchez-Paulete AR, Labiano S, Rodriguez-Ruiz ME, Azpilikueta A, Etxeberria I, Bolaños E, Lang V, Rodriguez M, Aznar MA, Jure-Kunkel M, Melero I. Sanchez-Paulete AR, et al. Eur J Immunol. 2016 Mar;46(3):513-22. doi: 10.1002/eji.201445388. Epub 2016 Feb 9. Eur J Immunol. 2016. PMID: 26773716 Review.
Cited by
- Short-term cultured tumor fragments to study immunotherapy combinations based on CD137 (4-1BB) agonism.
Eguren-Santamaría I, Rodríguez I, Herrero-Martin C, Fernández de Piérola E, Azpilikueta A, Sánchez-Gregorio S, Bolaños E, Gomis G, Molero-Glez P, Chacón E, Mínguez JÁ, Chiva S, Diez-Caballero F, de Andrea C, Teijeira Á, Sanmamed MF, Melero I. Eguren-Santamaría I, et al. Oncoimmunology. 2024 Jul 9;13(1):2373519. doi: 10.1080/2162402X.2024.2373519. eCollection 2024. Oncoimmunology. 2024. PMID: 38988823 Free PMC article. - Fcγ receptors and immunomodulatory antibodies in cancer.
Galvez-Cancino F, Simpson AP, Costoya C, Matos I, Qian D, Peggs KS, Litchfield K, Quezada SA. Galvez-Cancino F, et al. Nat Rev Cancer. 2024 Jan;24(1):51-71. doi: 10.1038/s41568-023-00637-8. Epub 2023 Dec 7. Nat Rev Cancer. 2024. PMID: 38062252 Review. - Synergistic effects of combined immunotherapy strategies in a model of multifocal hepatocellular carcinoma.
Ochoa MC, Sanchez-Gregorio S, de Andrea CE, Garasa S, Alvarez M, Olivera I, Glez-Vaz J, Luri-Rey C, Etxeberria I, Cirella A, Azpilikueta A, Berraondo P, Argemi J, Sangro B, Teijeira A, Melero I. Ochoa MC, et al. Cell Rep Med. 2023 Apr 18;4(4):101009. doi: 10.1016/j.xcrm.2023.101009. Epub 2023 Apr 10. Cell Rep Med. 2023. PMID: 37040772 Free PMC article. - First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors.
Hamid O, Chiappori AA, Thompson JA, Doi T, Hu-Lieskovan S, Eskens FALM, Ros W, Diab A, Spano JP, Rizvi NA, Wasser JS, Angevin E, Ott PA, Forgie A, Yang W, Guo C, Chou J, El-Khoueiry AB. Hamid O, et al. J Immunother Cancer. 2022 Oct;10(10):e005471. doi: 10.1136/jitc-2022-005471. J Immunother Cancer. 2022. PMID: 36302562 Free PMC article. Clinical Trial. - An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation.
Muik A, Altintas I, Gieseke F, Schoedel KB, Burm SM, Toker A, Salcedo TW, Verzijl D, Eisel D, Grunwitz C, Kranz LM, Vormehr M, Satijn DPE, Diken M, Kreiter S, Sasser K, Ahmadi T, Türeci Ö, Breij ECW, Jure-Kunkel M, Sahin U. Muik A, et al. Oncoimmunology. 2022 Feb 16;11(1):2030135. doi: 10.1080/2162402X.2022.2030135. eCollection 2022. Oncoimmunology. 2022. PMID: 35186440 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials